FDA panel voted 0-8 against approving Cornerstone Therapeutics (CRTX) lixivaptan
Tweet Send to a FriendGet Alerts CRTX Hot Sheet
Trade CRTX Now!
An panel voted 0-8 against approving Cornerstone Therapeutics's (NASDAQ: CRTX) lixivaptan.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- AVEO Pharma (AVEO) Says Partner Astellas Won't Submit Tivozani to EMA, Won't Fund Future Trials
- St. Jude Medical (STJ) Issues Encouraging Update for EnligHTN™ Multi-Electrode Renal Denervation System Following One Year
- Salix Pharma (SLXP) Reports Positive Results From Two Budesonide Foam Phase 3s
Create E-mail Alert Related Categories
FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
